BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

January 30, 2012 8:00 AM UTC

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.03 to $0.77 last week after FDA extended the PDUFA date for an NDA for inhaled Adasuve Staccato loxapine by three months to May 4. According to Alexza, FDA needs more time to review an updated REMS proposal submitted by the company. The product is under review to treat agitation in patients with schizophrenia or bipolar disorder.

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $0.20 to $12.14 on Friday before trading was halted ahead of news that FDA approved once-weekly Bydureon exenatide to treat Type II diabetes...